Search Results - immunotherapy

124 Results Sort By:
Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors
Application This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors. Key Benefits ST80...
Published: 11/13/2025   |   Inventor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee
Keywords(s): Drug Target Identification, Immunotherapy, Oncology Treatments, Small Molecule, Therapeutics
Category(s): TechPub Algolia > Drug Discovery
Protein Polymers for Organelle Engineering
Application Protein polymers enabling engineering of human membraneless organelles. Key Benefits Versatile applications across immunotherapy, cell therapy, and other therapeutic modalities. High biocompatibility with minimal reactivity with endogenous molecules. Deployable for organelle-level functionalization of human cells. Market Summary Proteins...
Published: 11/7/2025   |   Inventor(s): Felipe Quiroz, Ian Sicher, Spencer Hayes, Maria Giraldo-Castaño, Mariell Pascual, Alexa Avecilla
Keywords(s): Biomaterials, Cell Therapy, Immunotherapy, Protein and Peptide Therapeutics, Regenerative Medicine, Research Tools
Category(s): TechPub Algolia > Therapeutics
T Cells Targeting Misformed Proteins to Treat Neurodegenerative and Muscular Diseases
Antigen-specific immunotherapy with engineered cytotoxic T cells targeting misformed proteins to treat neurodegenerative and muscular diseases. Problem: Neurodegenerative and muscular diseases, such as amyotrophic lateral sclerosis (ALS), inclusion body myositis (IBM), and Alzheimer’s disease (AD), collectively affect over 5 million adults...
Published: 11/11/2025   |   Inventor(s): Ning Jenny Jiang, Shahab Chizari
Keywords(s): Bioengineering, Cell Therapy, Immunology, Immunotherapy, Inflammation, Neurodegenerative Diseases
Category(s): Technology Classifications > Diagnostics, Technology Classifications > Research Tools & Reagents, Technology Classifications > Therapeutics
TYRP-1 Chimeric Antigen Receptor to Treat Melanoma (UCLA Case No. 2020-106)
UCLA researchers in the Departments of Surgical Oncology and Microbiology, Immunology, & Molecular Genetics. have developed a CAR-T therapy that targets TYRP-1 for the treatment of melanoma. BACKGROUND: Immune checkpoint blockade (ICB) is a rapidly emerging immunotherapy approach that uses patients’ immune cells to treat cancer. In contrast...
Published: 9/15/2025   |   Inventor(s): Cristina Puig Saus, Antoni Ribas, Yvonne Chen
Keywords(s): Gene Therapy, Hematology, Immunotherapy, Research Methods
Category(s): Therapeutics > Hematology
Delivery of sustained local and systemic immunomodulation
Reducing treatment burden with continuous immune activation Background: Current immunotherapy approaches face significant limitations in both delivery and patient experience. Standard treatments rely on either systemic intravenous injections of antibodies or small molecules that require frequent clinic visits, or localized injections that provide...
Published: 6/13/2025   |   Inventor(s): Srinivas Sridhar, Needa Brown, Jennifer Guerriero, Alexander Gottlieb
Keywords(s): biocompatible, Biodegradable, Biomaterials, Cancer, Drug Delivery, Immunoengineering, immunotherapy, implant, Nanomedicine
Category(s): Technology Classifications > 1. Life Science > Therapeutics
Modified Hyaluronic Acid Hydrogels Containing Hyaluronidase for the Time‐Controlled and Targeted Release of anti-CTLA-4 and other Therapeutic Antibodies (UCLA Case No. 2016-526)
UCLA researchers from the Department of Medicine have developed a novel therapeutic platform for the administration of low-dose Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) antibody for cancer immunotherapy that synergizes with conventional PD-1 therapy while sparing systemic autoimmune toxicity. BACKGROUND: Immune checkpoint inhibitor (CPI)...
Published: 7/17/2025   |   Inventor(s): Michael Roth, Airi Harui
Keywords(s): Cancer Immunotherapy, Immunotherapy
Category(s): Platforms > Drug Delivery, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology
IgA Monoclonal Antibodies as a Prophylactic and Therapeutic Treatment for Dengue Virus Infection
Enables the prevention and treatment of dengue by avoiding the challenge of Antibody Dependent Enhancement. Background: Dengue virus is one of the most widespread vector-borne viral pathogens in the world. Nearly 400 million dengue virus infections occur each year, resulting in approximately 20,000 deaths. In addition, dengue-associated illness comprises...
Published: 8/21/2025   |   Inventor(s): Adam Waickman, Adam Wegman, Jeffrey Currier, Heather Friberg, Michael McCracken, Gregory Gromowski
Keywords(s): antibody, antibody therapy, biologics, biomedical, disease prevention, immunotherapy, monoclonal antibody, Technologies, viral immunology, viral pathogenesis
Category(s): Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Antibodies, Technology Classifications > Healthcare, Campus > Upstate Medical University
Gene Modifications to Enhance the Function of PSC-Derived T Cells and NK Cells (UCLA Case No. 2023-129)
UCLA researchers in the Department of Medicine have generated novel pluripotent stem cell derived T cells that exhibit improved survival, expansion, and anti-tumor efficacy for use in cell therapy treatments. BACKGROUND: The Food and Drug Administration has approved several chimeric antigen receptor-T (CAR-T) cell therapies since 2017 to combat lymphoma...
Published: 7/31/2025   |   Inventor(s): Christopher Seet
Keywords(s): CAR-T cell therapy, Immunotherapy, pluripotent stem cell (PSC), T-cell engineering
Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Gene Therapy And Editing
Reducing The Adverse Side Effects Of Using Native T-Cells To Destroy Cancer Cells
A Switchable Bispecific T-Cell Nanoengager (sBiTNE) to link T cells with cancer cells that can be reversed if off-tumor toxicity is detected. Problem: Compounds which link native T-cells with the surface antigens found on cancer cells have emerged as an effective treatment for blood malignancies and are currently being developed for solid tumors....
Published: 10/10/2025   |   Inventor(s): Michael Mitchell, Ningqiang Gong
Keywords(s): Bioengineering, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology, Protein/Peptide (Non-Antibody), Small Molecule
Category(s): Technology Classifications > Therapeutics
Anticancer IgG Against Multiple Epitopes on Live Tumors Upon Disruption of ‘Self’ Signaling by CD47
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis. Problem: Phagocytosis of ‘self’ cells is generally inhibited by a key macrophage checkpoint interaction between SIRPα on the macrophage and...
Published: 2/27/2025   |   Inventor(s): Dennis Discher, Jason Andrechak, Lawrence Dooling
Keywords(s): Antibody, Bioengineering, Cell Therapy, Drug Target, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
1 2 3 4 5 6 7 8 9 10 ...